MWNA
FATE icon

Marshall Wace North America’s Fate Therapeutics FATE Stock Holding History

Marshall Wace North America’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-44,175
Closed -$4.02M – 1584
2020
Q4 		$4.02M Buy
+44,175
New +$2.74M 0.02% 590
2020
Q3 		– Sell
-131,496
Closed -$4.51M – 1289
2020
Q2 		$4.51M Sell
131,496
-299,464
-69% -$8.93M 0.03% 383
2020
Q1 		$9.57M Buy
430,960
+144,488
+50% +$3.65M 0.07% 227
2019
Q4 		$5.61M Buy
286,472
+257,231
+880% +$4.09M 0.03% 372
2019
Q3 		$454K Buy
+29,241
New +$561K ﹤0.01% 828

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace North America's FATE Position: Q1 2021 in Review

Marshall Wace North America sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 44,175 shares — an estimated $4.02M sold.

Marshall Wace North America first reported a position in FATE in Q3 2019 and held it in 5 quarters. The position peaked at $9.57M in Q1 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • Marshall Wace North America reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 44,175 Fate Therapeutics shares in Q1 2021, an estimated $4.02M.
  • Marshall Wace North America first reported a position in Fate Therapeutics in Q3 2019 and held it in 5 quarters.
  • Marshall Wace North America's Fate Therapeutics position peaked at $9.57M in Q1 2020.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.